pharma Β· Critical Limb Ischemia (CLI) Β· Sarcoma Β· DSGN
Lxo Ireland Designated Activity Company
Lxo Ireland Designated drug portfolio β 61 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Portfolio lens on 61 drugs and development assets β regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Lxo Ireland Designated drug portfolio β 61 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Antineoplastic and immunomodulating agents (L02) compound in Lxo Ireland Designated's portfolio. Molecular target: Androgen receptor.
Development asset linked to Lxo Ireland Designated in public FDA and regional records.
Antineoplastic and immunomodulating agents (L01) compound in Lxo Ireland Designated's portfolio. Mechanism: EML4-ALK.
Cardiovascular system (C09) compound in Lxo Ireland Designated's portfolio. Mechanism: Renin inhibitor.
Antineoplastic and immunomodulating agents (L01) compound in Lxo Ireland Designated's portfolio. Mechanism: Somatic cell supplemental therapy.
Development asset linked to Lxo Ireland Designated in public FDA and regional records.
Development asset linked to Lxo Ireland Designated in public FDA and regional records.
Various (V09) compound in Lxo Ireland Designated's portfolio. Mechanism: Diagnostic agent.
Development asset linked to Lxo Ireland Designated in public FDA and regional records.
Development asset linked to Lxo Ireland Designated in public FDA and regional records.
US regulatory status: approved. Molecular target: Muscarinic acetylcholine receptor M1.
Development asset linked to Lxo Ireland Designated in public FDA and regional records.
US regulatory status: approved. Mechanism: Unknown.
US regulatory status: approved. Molecular target: Sodium channel protein type 4 subunit alpha.
US regulatory status: approved. Mechanism: Dihydrofolate reductase inhibitor.
US regulatory status: approved. Molecular target: Aromatic-L-amino-acid decarboxylase.
US regulatory status: approved. Molecular target: 26S proteasome.
US regulatory status: approved. Mechanism: Unknown.
Development asset linked to Lxo Ireland Designated in public FDA and regional records.
Development asset linked to Lxo Ireland Designated in public FDA and regional records.
Development asset linked to Lxo Ireland Designated in public FDA and regional records.
Antiinfectives for systemic use (J07) compound in Lxo Ireland Designated's portfolio. Mechanism: Biological vaccine - induces immune response.
US regulatory status: approved. Molecular target: Sodium/glucose cotransporter 2.
US regulatory status: approved. Molecular target: DNA topoisomerase II.
Development asset linked to Lxo Ireland Designated in public FDA and regional records.
US regulatory status: approved. Molecular target: Voltage-gated calcium channel.
Development asset linked to Lxo Ireland Designated in public FDA and regional records. Molecular target: Insulin receptor.
US regulatory status: approved. Molecular target: Enoyl-[acyl-carrier-protein] reductase [NADH] FabI.
Alimentary tract and metabolism (A16) compound in Lxo Ireland Designated's portfolio.
Antiinfectives for systemic use (J07) compound in Lxo Ireland Designated's portfolio. Mechanism: Biological vaccine - induces immune response.
Antiinfectives for systemic use (J07) compound in Lxo Ireland Designated's portfolio. Mechanism: Biological vaccine - induces immune response.
Antiinfectives for systemic use (J07) compound in Lxo Ireland Designated's portfolio.
Development asset linked to Lxo Ireland Designated in public FDA and regional records.
Development asset linked to Lxo Ireland Designated in public FDA and regional records.
Development asset linked to Lxo Ireland Designated in public FDA and regional records. Molecular target: Insulin receptor.
Development asset linked to Lxo Ireland Designated in public FDA and regional records.
Development asset linked to Lxo Ireland Designated in public FDA and regional records. Mechanism: Muscarinic acetylcholine receptor M3 antagonist.
US regulatory status: approved. Molecular target: D(3) dopamine receptor.
Development asset linked to Lxo Ireland Designated in public FDA and regional records.
Development asset linked to Lxo Ireland Designated in public FDA and regional records.
Development asset linked to Lxo Ireland Designated in public FDA and regional records. Mechanism: Mitochondrial complex I (NADH dehydrogenase) inhibitor.
Development asset linked to Lxo Ireland Designated in public FDA and regional records.
US regulatory status: approved. Molecular target: Tubulin.
US regulatory status: approved. Molecular target: 5-hydroxytryptamine receptor 3A.
Genito-urinary system and sex hormones (G03) compound in Lxo Ireland Designated's portfolio. Molecular target: Estrogen receptor.
US regulatory status: approved. Molecular target: B-lymphocyte antigen CD20.
US regulatory status: approved. Molecular target: Phosphodiesterase 4.
US regulatory status: approved. Molecular target: Sodium channel alpha subunit.
Development asset linked to Lxo Ireland Designated in public FDA and regional records.
Development asset linked to Lxo Ireland Designated in public FDA and regional records.
US regulatory status: approved. Molecular target: Dipeptidyl peptidase 4.
Development asset linked to Lxo Ireland Designated in public FDA and regional records.
Development asset linked to Lxo Ireland Designated in public FDA and regional records.
Nervous system (N01) compound in Lxo Ireland Designated's portfolio. Mechanism: Mu opioid receptor agonist.
Development asset linked to Lxo Ireland Designated in public FDA and regional records.
US regulatory status: approved. Mechanism: Diagnostic agent.
US regulatory status: approved. Molecular target: DNA topoisomerase 1.
Development asset linked to Lxo Ireland Designated in public FDA and regional records.
US regulatory status: approved. Molecular target: Progesterone receptor.
Development asset linked to Lxo Ireland Designated in public FDA and regional records.
Development asset linked to Lxo Ireland Designated in public FDA and regional records.